用活性位点抑制剂准SHP2阻断了信号传递和乳腺癌细胞表型
Dhanaji M Lade1, Yehenew M Agazie1
1One Medical Center Drive, Department of Biochemistry and Molecular Medicine, School of Medicine, West Virginia University, P.O. Box 9142, Morgantown, West Virginia 26506, United States.
ACS bio & med chem Au
|October 25, 2023
概括
一种名为CNBCA的新化合物有效地向致癌性Src同类型的酸化酸酸酶2 (SHP2) 蛋白. 这种抑制剂显示出更好的效能和选择性,抑制乳腺癌细胞生长和表型.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- Src同类型的胺酸酸酶2 (SHP2) 是一种瘤原蛋白,与癌症发展有关.
- 针对SHP2的向治疗对于治疗包括乳腺癌在内的各种癌症至关重要.
- 之前开发了一种活性位点抑制剂,CNBDA,在抑制乳腺癌细胞转化表型方面表现有前途.
研究的目的:
- 为了提高SHP2抑制剂的疗效和强度.
- 为了评估一种改性化合物,CNBCA,来自CNBDA.
- 评估CNBCA在抑制SHP2活性方面的有效性及其对乳腺癌细胞表型的影响.
主要方法:
- 对CNBDA进行化学修改以产生CNBCA.
- 在体外酶活性测试以确定针对SHP2,SHP1和PTP1B的效能和选择性.
- 细胞测试以评估SHP2抑制,信号通路调节以及对乳腺癌细胞增殖,殖民地形成和乳腺球生长的影响.
主要成果:
- 与原始化合物相比,CNBCA证明了针对SHP2酶活性的功效增加了5.7倍.
- 与其他蛋白质氨酸酸酶 (PTPs) 相比,CNBCA对SHP2具有增强的选择性.
- 在细胞环境中,CNBCA有效地抑制了全长的SHP2,降低了SHP2介导的信号传输,并抑制了关键的乳腺癌细胞表型.
结论:
- CNBCA是一种强效和选择性的SHP2抑制剂.
- 用CNBCA准SHP2有效地抑制了乳腺癌细胞的增殖,殖民地形成和乳腺球的生长.
- 在乳腺癌治疗中,CNBCA代表了针对SHP2的有前途的治疗策略.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:22Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K